New antibiotic combination for lung infection in people with or without cystic fibrosis
Treatments studied
Part of Infections clinical trials.
This trial tests a new combination of antibiotics to treat a hard-to-cure lung infection caused by Mycobacterium abscessus. It compares the new combination to the standard treatment, and people with cystic fibrosis and those without can take part.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 12 years old or older.
- You have a lung infection caused by a bacterium called Mycobacterium abscessus.
- You have not had a bad allergic reaction to any of the study antibiotics (sulbactam/durlobactam, ceftriaxone, amoxicillin, macrolides such as azithromycin, or clofazimine).
- If you are 12 to 17, your kidney function must be within a safe range (not severely reduced).
- You meet the broader criteria of the main FORMaT study (a related clinical trial).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a new antibiotic, Contezolid, can quickly reduce the amount of Mycobacterium abscessus in your lungs. It may be a treatment option if you have had a positive sputum test in the past 6 months.
This study tests an investigational medication called epetraborole for people with a chronic lung infection caused by Mycobacterium abscessus bacteria. You may be able to join if your infection is stable enough to delay standard treatment and you have symptoms like cough, fatigue, or weight loss.
This study tests if adding traditional Chinese medicine to standard treatment helps people with a lung infection called Mycobacterium abscessus. It may improve recovery and reduce side effects.
This is a special program for one patient with a lung infection from Mycobacterium abscessus. The trial uses a treatment with bacteriophages, which are viruses that attack specific bacteria.
This trial tests whether omadacycline (an antibiotic) can safely and effectively treat a rare lung infection caused by Mycobacterium abscessus bacteria. If you have this infection, this study may help doctors understand if this antibiotic works better than current treatments.
This study looks for the best way to treat Mycobacterium abscessus (MABS), a difficult lung infection. You may join a treatment group, or first join an observation group and possibly move into treatment later if you meet the criteria.
Hear when a new Mycobacterium Abscessus Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.